As part of our integrated Pharmaceutical Development & Manufacturing platform, we execute end-to-end Drug Substance Development programs that include advanced Cell Therapy Product Development. We focus on rigorous, phase-appropriate CMC strategies and laboratory bioprocess innovation to convert source-matched cell materials into consistent, well-characterized drug substances ready for downstream progression.
Overview of Autologous Cell Therapy Product Development
Autologous cell therapy involves collecting cells from an individual patient, manipulating or expanding them ex vivo, and re-administering them to the same patient for therapeutic benefit. Because each product batch is patient-specific, autologous therapies present unique scientific, manufacturing, regulatory, and logistical challenges compared with allogeneic or small-molecule products.Typical laboratory activities include cell isolation/enrichment, activation and media design, optional genetic modification, expansion, formulation—each under a quality-by-design (QbD) framework. Common examples include CAR-T cell therapies, tumor-infiltrating lymphocytes (TILs), autologous stem cell therapies, and gene-modified hematopoietic cells.
Fig.1 Schematic diagram of CAR-T cell therapy design.
Our Services
We provide an R&D-centric, CMC-aligned suite of laboratory services spanning cellular drug substance development, genetic modification process development, and technical documentation support.
Cell Isolation & Enrichment Development Service
We optimize isolation schemas for relevant cell subsets (e.g., T cells, NK cells, HSPCs, dendritic precursors) using magnetic selection, density systems, or flow-based sorting under closed-system constraints. Our work balances recovery, purity, and downstream readiness, while qualifying key raw materials (beads, cytokines, buffers) for identity, performance, and traceability.
Activation & Media/Feed Development Service
We tailor activation approaches (bead-mediated or surface-mediated) and design basal media, supplements, and cytokine regimens to achieve target phenotypes while controlling exhaustion markers. DoE interrogates osmolality, feed timing, and redox balance. In-process controls track viability, phenotype, and residual activation reagents to maintain consistent cell state prior to expansion or modification.
Genetic Modification Process Development Service
For programs requiring genetic insertion or editing (e.g., CAR, TCR, or nuclease-guided edits), we develop transduction or electroporation workflows that balance efficiency and cell fitness. Parameters include multiplicity/exposure, recovery windows, and supportive cytokine environments. We qualify assays for vector copy number, transgene expression kinetics, on-target performance indicators, and residual reagent controls.
In-Process Control & Analytical Development Service
We build orthogonal analytical panels for identity (immunophenotyping, gene expression), purity (subset composition, residual beads/impurities), potency (mechanism-aligned functional or surrogate assays), and safety attributes (endotoxin, sterility strategy, mycoplasma approach).
Technical Documentation Support Service
We compile process descriptions, method write-ups, specification rationales, and control-strategy narratives aligned to prevailing expectations for cellular drug substances.
Our Autologous Cell Therapy Product Development Portfolio
We provide development services for following autologous cell therapy product categories (including but not limited to):
- Autologous CAR-T cells
- Autologous TCR-T cells
- Autologous tumor-infiltrating lymphocyte (TIL) products
- ...
- Autologous dendritic cell products
- Autologous HSPC products (Gene modification)
- Autologous NK cells
We deliver autologous-specific, laboratory-focused CMC solutions encompassing strategic planning, process development, analytical characterization, and comprehensive technical documentation. Our approach is tailored to the unique challenges of same-source cell therapies, enabling the transformation of patient- or donor-derived starting materials into consistent, well-controlled, and well-characterized drug substances. By integrating sound scientific rationale with practical laboratory execution and regulatory awareness, we help identify and mitigate development risks early, establish robust control strategies, and ensure data packages are suitable for downstream manufacturing and regulatory interactions. Engage our team to de-risk development, strengthen technical confidence, and accelerate progress toward manufacturing readiness and clinical advancement.
Our products and services are for research use only.
